Estimating the Prevalence of Congenital Cytomegalovirus Infection due to Primary Maternal Infection in the United States: A Probabilistic Risk Assessment Model
Birth Defects Research · 2026
DOI: 10.1002/bdr2.70025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Birth Defects Research, 2026. Verfasst von Nicole G Wiley und 4 weiteren Autor:innen. Beteiligte Einrichtung: ASRT Inc., Contractor for National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, US…. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Pregnancy Complications, Infectious. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural CDC HHS.
Abstract (Originalsprache)
Background
Transplacental transmission of cytomegalovirus (CMV) after primary maternal infection during the first trimester of pregnancy is associated with the most severe sequelae from congenital CMV (cCMV) infection. We estimated the prevalence of cCMV infection due to primary maternal CMV infection in the United States.
Methods
We built a probabilistic risk assessment model inputting 2022 national natality data, national CMV seroprevalence estimates among females 15–49 years, and published vertical transmission rates to estimate cCMV infection prevalence and distribution by maternal age group, parity, and trimester of infection during pregnancy.
Results
The estimated prevalence of cCMV infection due to primary maternal infection was 3.4 (95% CI: 2.0–6.0) per 1000 live births, resulting in 12,310 infants with cCMV infection in 2022. cCMV prevalence was higher among infants born to females 15–19 and 20–29 years (4.7 and 4.2 per 1000, respectively) than those born to females 30–39 and 40–49 years (2.6 per 1000, both). cCMV prevalence was higher among infants of primipara than multipara females (4.0 vs. 3.0 per 1000). Most infants with cCMV infection were born to females 20–29 years, either primipara (29%) or multipara (27%), and females 30–39 years, multipara (24%). Approximately 3160 (26%) cCMV infections resulted from first‐trimester maternal infection.
Conclusion
Assuming an overall cCMV prevalence of 4.4 per 1000 live births, 77% of cCMV infections in the United States may be attributable to primary maternal infections. Data on group‐specific prevalence of cCMV infection following primary maternal infection will be useful to inform preventative strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- ASRT Inc., Contractor for National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
- Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
- Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
- Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
ORCID-Profile: Nicole G Wiley
Förderung
- Intramural CDC HHS
Zitieren
APA
Wiley, N. G., Lutz, C. S., Thomas, M. M., Ortega Sanchez, I. R., & Lanzieri, T. M. (2026). Estimating the Prevalence of Congenital Cytomegalovirus Infection due to Primary Maternal Infection in the United States: A Probabilistic Risk Assessment Model. Birth Defects Research. https://doi.org/10.1002/bdr2.70025
Vancouver
Wiley NG, Lutz CS, Thomas MM, Ortega Sanchez IR, Lanzieri TM. Estimating the Prevalence of Congenital Cytomegalovirus Infection due to Primary Maternal Infection in the United States: A Probabilistic Risk Assessment Model. Birth Defects Research. 2026. doi:10.1002/bdr2.70025
BibTeX
@article{Wiley2026,
author = {Wiley, Nicole G and Lutz, Chelsea S and Thomas, Michael M and Ortega Sanchez, Ismael R and Lanzieri, Tatiana M},
title = {Estimating the Prevalence of Congenital Cytomegalovirus Infection due to Primary Maternal Infection in the United States: A Probabilistic Risk Assessment Model},
journal = {Birth Defects Research},
year = {2026},
doi = {10.1002/bdr2.70025}
}
EUVIMED